2014
DOI: 10.1007/s15010-014-0711-4
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of chronic pulmonary aspergillosis with voriconazole: review of a case series

Abstract: A reasonable proportion of patients achieved cure or improvement with voriconazole, but 28.5 % of treated patients had to discontinue therapy because of toxicity. The high mortality makes it difficult to fully assess the real efficacy of voriconazole and to establish the correct duration of therapy.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
17
0
1

Year Published

2015
2015
2023
2023

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 27 publications
(19 citation statements)
references
References 39 publications
1
17
0
1
Order By: Relevance
“…Oral triazole therapy for CCPA is now considered the standard of care. Oral voriconazole is also effective for CCPA with an acceptable tolerability in several studies as primary therapy (SoR A and QoE II) or after itraconazole (either because of failure or intolerance) (SoR A and QoE II) [15,30,[89][90][91][92]. A retrospective cohort study supports the evidence that oral posaconazole may be a potential alternative treatment (SoR B and QoE II) [59].…”
Section: Treatment and Follow-upmentioning
confidence: 52%
“…Oral triazole therapy for CCPA is now considered the standard of care. Oral voriconazole is also effective for CCPA with an acceptable tolerability in several studies as primary therapy (SoR A and QoE II) or after itraconazole (either because of failure or intolerance) (SoR A and QoE II) [15,30,[89][90][91][92]. A retrospective cohort study supports the evidence that oral posaconazole may be a potential alternative treatment (SoR B and QoE II) [59].…”
Section: Treatment and Follow-upmentioning
confidence: 52%
“…Despite the substantial amount of Aspergillus spp. in the cavities of patients with CPA, culture positivity from sputum samples is lower than expected (41%–81%) and is probably biased toward culture-positive cases ( 21 , 22 , 64 67 ). One reason for this lower sensitivity is the inoculation of culture plates with very small volumes of sputum ( 65 , 68 ) as is done for bacterial culture.…”
Section: Resultsmentioning
confidence: 75%
“…Evidence for the use of voriconazole for the treatment of CPA is supported by two prospective open multicentre trials and a review of case series, all of which involve small numbers of patients [ 74 , 140 , 141 ]. Overall response rates in these studies vary between 42.9% and 60.6%, with responses appearing to be greater in those with chronic necrotizing pulmonary aspergillosis (now known as SAIA) rather than chronic cavitary disease [ 74 , 140 , 141 ]. This highlights the importance of accurate stratification of patients in all future studies of antifungal efficacy.…”
Section: Treatment Optionsmentioning
confidence: 99%